Inflammatory signals in cells
In cultured cells, KPV reduced the activity of NF-κB and other signals involved in inflammation.
Investigational · not FDA-approved
Educational information about an investigational peptide that is not FDA-approved: research, limits, risks and regulatory status.
Introduction
KPV is a very small peptide that researchers study for its effects on inflammation in cells and animals. Promotional materials often present it as a treatment for gut, skin or immune problems, but those uses have not been shown in people.
This page explains what KPV is, what research has explored, what is still unknown and what its regulatory status is. KPV is not an FDA-approved medicine, and no benefit in people has been established.
Overview
KPV is a tripeptide made of three amino acids: lysine, proline and valine. It corresponds to the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the body produces that takes part in regulating inflammation and skin pigmentation.
KPV is not approved by the FDA for any use. When it is offered, it is usually as a compounded product, whose quality and strength are not reviewed by the FDA in the way approved medicines are.
Mechanisms
These mechanisms come from laboratory research; they do not show a benefit in people.
In cultured cells, KPV reduced the activity of NF-κB and other signals involved in inflammation.
Cell studies show that a peptide transporter (PepT1) carries KPV into cells of the intestinal lining.
KPV is the end fragment of alpha-MSH; whether it acts through the same receptors is still being studied.
Preclinical research
Most published research on KPV has been done in cell cultures and in mice. In mouse models of intestinal inflammation (colitis), KPV — including experimental oral forms designed to reach the colon — reduced some markers of inflammation. Other laboratory studies have explored skin inflammation, wound models and activity against certain microbes.
These studies are early-stage. The amounts, forms of delivery and conditions used in animals cannot be applied directly to people.
Next step
If you have digestive, skin or inflammation-related concerns, a medical evaluation helps identify the cause and proven treatment options.
Evidence
No published randomized controlled trial has shown that KPV is effective or safe for any condition.
The available results come mainly from cultured cells and mouse models of inflammation.
Several studies used special oral or topical formulations that differ from compounded peptide products.
Side effects, interactions and long-term effects in people have not been studied systematically.
Preclinical vs. human
Results in cells and animals often do not translate to people. Reduced inflammation, recovery of injured tissue, better gut health, healthier skin and a more balanced immune response have not been established as clinical results of KPV in people.
KPV is not a substitute for the diagnosis and treatment of inflammatory bowel disease, skin conditions or immune disorders by your doctor or specialist.
Regulatory status
KPV is not approved by the FDA for any use. The FDA has raised safety concerns about the use of several peptides in compounded drugs, and the current status of KPV must be confirmed before any use. Products sold online as "research peptides" are not intended for use in people.
Risks
The safety of KPV in people has not been established in clinical trials.
Compounded or online peptides can vary in purity, strength and sterility.
Any injected product can cause redness, pain, infection or allergic reactions.
Stomach upset, nausea, headache and fatigue have been mentioned, but how often they occur is unknown.
Because KPV is studied for its effects on inflammation, how it interacts with immune-modifying treatments is unknown.
Using an unproven product can delay the evaluation of symptoms that need medical care.
Safety
KPV may not be appropriate, and should be discussed with a provider first, if any of these situations applies to you:
Evaluation
Digestive, skin or inflammatory symptoms, medications and prior treatments.
Causes are evaluated and treated with established care, with referral to a specialist when needed.
Your provider explains approval status, evidence and risks before any decision.
FAQ
Clear answers to help you prepare.
No. KPV is not approved by the FDA for any use, and it has not been shown to be safe and effective in clinical trials in people.
Studies in cells and animals suggest anti-inflammatory effects, but KPV has not been shown to reduce inflammation, heal the gut lining, or improve skin or immune health in people. Inflammatory bowel and skin conditions should be managed with established treatments by your doctor.
No. KPV is a three-amino-acid fragment of alpha-MSH. It is a much smaller molecule, and researchers are still studying how it acts and whether it shares any of alpha-MSH's effects.
Its safety in people is not known. There are no controlled human studies, and compounded or online products can vary in quality. Talk with a provider before considering any investigational product.
This page is educational. It does not give doses, schedules or instructions; any decision about a medicine is made only by a licensed provider after an individual evaluation.
Information on this page is educational and does not replace medical evaluation. Treatment options are determined individually.